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1. Introduction  
Various actin-depolymerizing agents have been found in 
marine invertebrates, and some show extremely potent 
cytotoxicity. They are considered to be useful for the 
development of novel pharmacological tools for analyzing actin-
mediated cell functions, such as muscle contraction, cell motility, 
and cytokinesis. Among them, mycalolide B (1) is a unique tris-
oxazole macrolide that was isolated from the marine sponge 
Mycale sp. (Fig. 1),1 which exhibits various biological activities, 
such as cytotoxicity against B16 melanoma cells, inhibition of 
actomyosin Mg2+–ATPase,2 and antimycotic activity against 
several pathogenic fungi.3 It has been suggested that several 
antifungal compounds might serve as a chemical defense against 
microbial attack for marine invertebrates that lack cellular 
immune systems.4 
Many tris-oxazole macrolides that are structurally related to 
mycalolides have been isolated, such as ulapualides,5 
halichondramides,6 jaspisamides,7 and kabiramides;8 and all of 
these exhibit potent actin-depolymerizing properties. X-ray 
analyses of the actin–kabiramide C,9 actin–jaspisamide A,9 and 
actin–ulapualide A complexes 10 revealed that their side-chain 
parts (C25–C35) intercalate into the hydrophobic cleft between 
subdomains 1 and 3 of actin. Furthermore, aplyronine A (4), 
which shows potent antitumor activities against several cancers, 
also possesses an actin-binding side-chain part similar to that of 
mycalolides.11–13 Photoaffinity labeling experiments 14 and X-ray 
crystallographic analysis 15 have also established that the 
interactions of actin–aplyronines are closely related to those of 
mycalolides. Meanwhile, the macrocyclic functional groups of 
aplyronines, i.e., the C7 trimethylserine and C9 hydroxyl groups, 
have been shown to be essential for its potent cytotoxicity.16 Thus, 
we expected that the structurally unique macrolactone moieties in 
mycalolides and related tris-oxazole macrolides could serve as a 
pharmacophore that enable them to specifically interact with 
biomacromolecules to exhibit various biological activities. 
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Fig. 1. 
 
Due to their complexity and unique biological activities, there 
have been several synthetic studies on tris-oxazole macrolides.17 
Recently, total syntheses of mycalolide A 18 and ulapualide A 19 
have been described. We previously synthesized the C22–C35 
part 2 of mycalolide B, which showed significant actin-
depolymerizing activity corresponding to that of 1, but no 
cytotoxicity.20 However, mycalolide derivatives that consist of 
the tris-oxazole macrolactone part alone have not yet been 
synthesized and characterized. It was expected that ulapualides 
and halichondramide could incorporate several metal ions (i.e. Fe, 
Co, Cu) to form coordination complexes, in which the oxazole N 
atoms and the O atoms of C3 and C7 oxygenated functional 
groups may coordinate to metals.21 Thus, it is possible that the 
lactone moiety of mycalolides and related tris-oxazole 
macrolides might serve as an ionophore, which could contribute 
to their unique bioactivities. Here we describe the synthesis of 
tris-oxazole macrolactone analogs 3 through the use of ring-
closing metathesis (RCM) along with their biological activities. 
2. Results and discussion 
2.1  Molecular modeling studies 
First, we estimated the three-dimensional structure of the 
macrolactone part of 1 by using a molecular modeling method. A 
conformational analysis and density functional theory (DFT) 
calculation of tris-oxazole macrolactone analogs 3 revealed that 
the 19E isomer is lower in energy than the 19Z isomer by 5.4 
kJ/mol at the B3LYP/6-31G(d) level of theory. (Fig. 2) 22 This 
difference was almost identical to that for (E)- and (Z)-2-(1-
butenyl)oxazoles (6.2 kJ/mol). Conjugated tris-oxazoles, the C7 
conjugated ketones, and the C19 olefin moieties in both (E)- and 
(Z)-3 have an almost planar orientation, which suggested that 
their conformations are considerably fixed. The distances 
between the C3 hydroxyl H atom and two oxazole N atoms of 
(E)-3 were less than 3.1 Å, which strongly indicated the presence 
of intramolecular hydrogen bonding. In contrast, the C3 hydroxyl 
group in (Z)-3 did not interact with the tris-oxazole moiety. 
These significant differences in the stereostructures of E- and Z-
isomers led us to synthesize both isomers and compare their 
biological activities. 
 
 
Fig. 2.  Optimized structures and relative energies of 3 at the B3LYP/6-
31G(d) level of theory. Values in (E)-3 represent the calculated distances 
between the C3 hydroxyl H atom and the three oxazole N atoms (Å). 
 
2.2  Synthesis of the tris-oxazole macrolactone analogs of 
mycalolides 
Based on the finding that olefin metathesis is a useful method 
for connecting the C19–C20 double bonds in mycalolide 
analogs,23 we considered that the assembly of two fragments via 
Ni/Cr-mediated Nozaki–Hiyama–Kishi coupling 24 at C6–C7 and 
RCM at C19 could efficiently afford 3. The synthesis started with 
syn-homoallylic alcohol 6, which was prepared from methyl (S)-
(+)-3-hydroxy-2-methylpropionate (5) 25 (Scheme 1). 
Methylation of compound 6 by methyl trifluoromethanesulfonate 
(MeOTf) (90%) and removal of the tert-butyldiphenylsilyl 
(TBDPS) group by tetra-n-butylammonium fluoride (TBAF) 
gave primary alcohol 8 (96%). Hydrolysis of methyl ester in 9 23b 
with LiOH afforded carboxylic acid 10 (80%), which was 
condensed with 8 by the Yamaguchi procedure to afford ester 11 
in 92% yield. Fragment coupling between 11 and aldehyde 12 23b 
by a Ni/Cr-mediated reaction (73%) was followed by oxidation 
of the C7 allylic alcohol with Dess–Martin periodinane (DMP) to 
afford the RCM precursor 14 (94%). Alternatively, removal of 
the TBDPS group of 14 by TBAF with acetic acid (AcOH) gave 
another RCM precursor 15 in 72% yield.  
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Scheme 1. Synthesis of the RCM precursors 14 and 15. Reagents and 
conditions: (a) MeOTf, 2,6-di-tert-butylpyridine, CH2Cl2, rt, 90%; (b) TBAF, 
THF, rt, 96%; (c) LiOH, THF–H2O, 40 °C, 80%; (d) 2,4,6-Cl3C6H2COCl, 
Et3N, THF, rt, then DMAP, benzene, rt, 92%; (e) CrCl2, NiCl2, THF–DMF 
(3:1), rt, 73%; (f) Dess–Martin periodinane, pyridine, CH2Cl2, 0 °C, 94%; (g) 
TBAF, AcOH, THF, rt, 72%.  
 
With the key intermediates 14 and 15 in hand, RCM reactions 
were examined (Table 1). Despite the calculation results that 
19E-macrolactone 3 was lower in energy than its 19Z-isomer, 
treatment of 14 with 30 mol% of 2nd-generation Hoveyda–
Grubbs catalyst 26 in refluxing toluene (1 mM) gave tris-oxazole 
lactone 16 as a separable 1:1.9 mixture of E- and Z-isomers in 
61% yield (entry 1). Similarly, the reaction at 40 °C in hexane 
preferred the Z-isomer (E/Z = 1.0/2.5) (entry 2).27 With the use of 
benzotrifluoride as a solvent,28 the RCM reaction was completed 
in 1 h, and the yield of the E-isomer was improved (entry 3). 
Interestingly, the E/Z product ratio was reversed at lower 
temperature in the same solvent (entry 4) or in ethyl acetate 
(entry 5). Furthermore, refluxing conditions in dichloromethane 
gave the best results (82%, E/Z = 1.8/1.0) (entry 6).29 These 
results suggested that both the solvent polarity and reaction 
temperature significantly affected the stereoselectivity of the 
RCM reaction of 14, and that the formation of C=C bonds in 16 
would take place under kinetic control.23b 
Table 1 
Ring-closing metathesis of 14 
 
 
Entry  Reaction conditions [a]  Yield of  
  16 (%) 
E/Z ratio Yield of 
dimer (%) 
1  toluene, reflux, 1.5 h 61 1.0 / 1.9 5 
2  Hexane, 40 °C,  24 h 73 1.0 / 2.5 9 
3  C6H5CF3, reflux, 1 h 69 1.0 / 1.3 7 
4  C6H5CF3, 40 °C,  24 h 77 1.3 / 1.0 6 
5  EtOAc, 40 °C,  9 h  78 1.2 / 1.0 9 
6  CH2Cl2, reflux, 9 h 82 1.8 / 1.0 5 
a Concentration = 1 mM. 2nd Hoveyda–Grubbs catalyst (30 mol%) was used. 
 
Finally, removal of the TBDPS groups of the stereoisomers 
(E)- and (Z)-16 by TBAF with AcOH afforded trisoxazole 
macrolactones (E)- and (Z)-3 in respective yields of 87% and 
91% (Scheme 2). 
 
 
Scheme 2. Synthesis of tris-oxazole macrolactones 3. Reagents and 
conditions: (a) TBAF, AcOH, THF, rt, 87% for (E)-3 and 91% for (Z)-3. 
 
For comparison, we also examined the RCM reaction of C3 
hydroxyl analog 15 (Scheme 3). While the reaction was slower 
than that of silyl ether 14 (see Table 1, entry 6), refluxing 
conditions in dichloromethane (1 mM) gave macrolactone 3 in 
72% yield, and the E-selectivity was slightly improved (E/Z = 
2.5/1.0). Thus, it is expected that the RCM precursor 15 would 
have a specific conformation to prefer the formation of the E-
isomer, due to intramolecular hydrogen bonding between the 
hydroxyl H atom and oxazole N atom(s), which might enable 
terminal olefins to move toward each other. 
 
 
Scheme 3. Ring-closing metathesis of 15. 
 
2.3  Biological activities  
While the E- and Z-stereoisomers of tris-oxazole macrolactone 
analogs 3 both exhibited moderate cytotoxicity against human 
epithelial carcinoma HeLa S3 cells, they were approximately 100 
times less cytotoxic than mycalolide B (1) (Table 2). Furthermore, 
they exhibited no significant actin-depolymerizing effects. In 
addition, neither (E)- nor (Z)-3 exhibited in vitro antimycotic 
activity against several pathogenic fungi (Aspergillus fumigatus, 
Candida albicans, and Trichophyton mentagrophytes) or normal 
fungi (Mucor hiemalis and Rhizopus nigricans) at 30 µg/mL. 
Thus, both the side-chain and the macrolactone moieties were 
suggested to be essential for the potent cytotoxicity or 
antimycotic activity of the parent molecules.30 
This is an author version based on a template by Elsevier.
Tetrahedron 4 
 
Table 2 
Biological activities of mycalolide analogs 
Compound  Cytotoxicity (HeLa S3)  
IC50 (µg/mL)  
Actin-depolymerizing activity 
EC50 (µM) [a] 
Mycalolide B (1)        0.020       1.4 [b] 
2        >10 [b]       2.7 [b] 
(E)-3        2.4       >30 
(Z)-3         1.9       >30 
a Activity was monitored by measuring the fluorescence intensity of pyrenyl 
actin. Values indicate the concentrations required to depolymerize F-actin (3 
μM) to 50% of its control amplitude.  
b See ref. 20. 
 
3. Conclusions  
In conclusion, we concisely synthesized tris-oxazole 
macrolactone analogs of mycalolides by using Nozaki–Hiyama–
Kishi coupling at C6–C7, esterification, and RCM at C19 as key 
steps. We established that both the side-chain (actin-binding) 
moiety and the macrolactone moiety were essential for the potent 
biological activities of the parent molecules. Further studies on 
the structure-activity relationships for mycalolides and related 
actin-targeting natural products as well as their mechanisms of 
action are currently underway. 
4. Experimental Section  
4.1  General 
All chemicals were obtained commercially unless otherwise 
noted. Organic solvents and reagents for moisture-sensitive 
reactions were distilled by the standard procedure. Anhydrous 
CH2Cl2, tetrahydrofuran (THF), and N,N-dimethylformamide 
(DMF) were obtained commercially. Column chromatography 
was performed using silica gel BW-820MH or FL60D (75–200 
or 45–75 µm, Fuji Silysia Co., Aichi, Japan) or a Yamazen 
preparative silica gel (40 µm). All moisture-sensitive reactions 
were performed under an atmosphere of argon or nitrogen, and 
the starting materials were azeotropically dried with benzene 
before use. Merck precoated silica gel 60 F254 plates were used 
for thin layer chromatography (TLC). 
4.2  Spectroscopic analysis 
1H and 13C nuclear magnetic resonance (NMR) spectra were 
recorded on a Bruker Biospin AVANCE 600 spectrometer (600 
MHz for 1H and 150 MHz for 13C), or a JEOL EX-270 
spectrometer (270 MHz for 1H). Chemical shifts were reported in 
parts per million (ppm) with coupling constants (J) in hertz 
relative to the solvent peaks, dH 7.26 (residual CHCl3) and dC 
77.0 for CDCl3, respectively. Optical rotations were measured 
with a JASCO DIP-1000 polarimeter using the sodium D line. 
Infrared (IR) spectra were recorded on a JASCO FT/IR-230 
spectrometer. High-resolution electrospray ionization mass 
spectra (HR-ESIMS) were measured on a QSTAR Pulsar i 
spectrometer (Applied Biosystems) or an AccuTOF CS 
spectrometer (JEOL).  
4.3  Synthesis and spectroscopic data of mycalolide 
derivatives  
4.3.1.  Methyl ether 7.  To a stirred solution of (–)-secondary 
alcohol 6 (787 mg, 2.14 mmol, >99%ee, syn/anti = 93/7) in dry 
CH2Cl2 (4.8 mL) were added methyl trifluoromethanesulfonate 
(0.72 mL, 6.4 mmol) and 2,6-di-tert-butylpyridine (1.5 mL, 6.4 
mmol) at 0 °C under a nitrogen atmosphere. After being stirred 
for 20 h at room temperature, the reaction mixture was quenched 
with sat. sodium bicarbonate aq. (15 mL) at 0 °C, stirred for 45 
min at room temperature, and extracted with CH2Cl2 (5 mL ´ 4). 
The combined extracts were washed with water and brine, dried 
with Na2SO4, and concentrated. The crude material was purified 
with a Yamazen preparative SiO2 column (30 g, hexane / EtOAc 
= 100/0 to 95/5) to give methyl ether 7 (737 mg, 90%, syn/anti = 
93/7) as a colorless oil. 7: Rf 0.41 (hexane / EtOAc = 9:1); [a]D25 
+9.0 (c 1.09, CHCl3); 1H NMR (600 MHz, CDCl3) d 7.72–7.65 
(m, 4H), 7.46–7.36 (m, 6H), 5.81 (ddt, J = 17.2, 10.2, 7.0 Hz, 
1H), 5.08 (d, J = 17.2 Hz, 1H), 5.05 (d, J = 10.2 Hz, 1H), 3.69 
(dd, J = 10.0, 7.2 Hz, 1H), 3.54 (dd, J = 10.0, 6.1 Hz, 1H), 3.45 
(dt, J = 3.9, 6.8 Hz, 1H), 3.36 (s, 3H), 2.36 (dddt, J = 13.9, 7.0, 
6.8, 1.2 Hz, 1H), 2.23 (dddt, J = 13.9, 7.0, 6.8, 1.0 Hz, 1H), 1.87 
(dddq, J = 7.8, 6.1, 3.9, 7.0 Hz, 1H), 1.08 (s, 9H), 0.89 (d, J = 7.0 
Hz, 3H); 13C NMR (150 MHz, CDCl3) d 135.6 (d, 4C), 135.5 (d), 
134.0 (s), 133.9 (s), 129.5 (d, 2C), 127.6 (d, 4C), 116.5 (t), 80.6 
(d), 65.9 (t), 57.9 (q), 38.7 (d), 35.6 (t), 26.9 (q, 3C), 19.3 (s), 
10.9 (q); IR (CHCl3) 3073, 3009, 2962, 2932, 2859, 1640, 1589, 
1472, 1428, 1389, 1362, 1217, 1112, 1088, 998, 918, 824, 705 
cm–1; HRMS (ESI) m/z 405.2207 (calcd for C24H34NaO2Si 
[M+Na]+, D –1.9 mmu). 
4.3.2.  Primary alcohol 8.  To a stirred solution of 7 (1.01 g, 2.64 
mmol, syn/anti = 93/7) in dry THF (18 mL) was added a 1 M 
solution of tetra-n-butylammonium fluoride in THF (3.2 mL, 3.2 
mmol) at 0 °C under a nitrogen atmosphere. After being stirred 
for 4 h at room temperature, the reaction mixture was quenched 
with sat. NH4Cl aq. (10 mL), and extracted with Et2O (10 mL ´ 
3). The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated. The crude material was purified with 
a SiO2 column (40 g, hexane / Et2O = 9/1 to 1/1) to give primary 
alcohol 8 (366 mg, 96%, syn/anti = 93/7) as a colorless oil. 8: Rf 
0.15 (hexane / Et2O = 7:3); [a]D25 +17.2 (c 1.31, CHCl3); 1H 
NMR (600 MHz, CDCl3) d 5.81 (ddt, J = 17.0, 10.7, 7.2 Hz, 1H), 
5.10 (d, J = 17.0 Hz, 1H), 5.04 (d, J = 10.7 Hz, 1H), 3.65 (dd, J = 
10.7, 7.1 Hz, 1H), 3.58 (dd, J = 10.7, 4.6 Hz, 1H), 3.38 (s, 3H), 
3.36 (dt, J = 3.4, 6.6 Hz, 1H), 2.56 (br s, 1H), 2.38 (dddt, J = 14.0, 
7.2, 6.6, 1.3 Hz, 1H), 2.20 (dddt, J = 14.0, 7.2, 6.6, 1.1 Hz, 1H), 
1.95 (m, 1H), 0.89 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) d 135.2 (d), 116.8 (t), 83.8 (d), 66.3 (t), 57.6 (q), 37.0 (d), 
34.6 (t), 11.1 (q); IR (CHCl3) 3632, 3484, 3081, 3009, 2979, 
2935, 2832, 1641, 1460, 1428, 1380, 1361, 1236, 1192, 1083, 
1032, 918, 780, 773, 726 cm–1; HRMS (ESI) m/z 167.1050 (calcd 
for C8H16NaO2 [M+Na]+, D +0.2 mmu).  
4.3.3.  Carboxylic acid 10.  To a stirred solution of (+)-methyl 
ester 9 (302 mg, 0.593 mmol, 99%ee, E/Z = 6.7/1) in THF (3 
mL) was added 1 M lithium hydroxide aq. (3.6 mL, 3.6 mmol) at 
0 °C. After being stirred for 23 h at 40 °C, the reaction mixture 
was acidified with 1 M HCl aq. (5 mL) and extracted with Et2O 
(5 mL ´ 4). The combined extracts were washed with brine, dried 
with Na2SO4, and concentrated. The crude material was purified 
with a SiO2 column (10 g, hexane / EtOAc = 9/1 to 5/1) to give 
carboxylic acid 10 (234 mg, 80%, E/Z = 6.7/1) as a colorless oil. 
10: Rf 0.42 (hexane / EtOAc = 2:1); [a]D25 +33.7 (c 1.22, CHCl3); 
1H NMR (270 MHz, CDCl3) d 7.75–7.64 (m, 4H), 7.50–7.35 (m, 
6H), 6.38 (dt, J = 14.4, 7.6 Hz, 1H), 5.98 (d, J = 14.4 Hz, 1H), 
4.18 (tt, J = 5.9, 5.9 Hz, 1H), 2.49 (dd, J = 6.7, 6.5 Hz, 2H), 
2.30–2.16 (m, 2H), 1.06 (s, 9H). COOH signal was not observed; 
13C NMR (150 MHz, CDCl3) d 177.1 (s), 141.5 (d), 135.9 (d, 4C), 
133.4 (s, 2C), 129.9 (d), 129.8 (d), 127.7 (d, 4C), 78.2 (d), 68.8 
(d), 43.1 (t), 41.2 (t), 26.9 (q, 3C), 19.3 (s); IR (CHCl3) 3073, 
3054, 3010, 2961, 2933, 2897, 2860, 1712, 1606, 1589, 1472, 
1428, 1363, 1221, 1111, 951, 822, 786, 704 cm–1; HRMS (ESI) 
m/z 517.0701 (calcd for C22H27INaO3Si [M+Na]+, D +2.9 mmu). 
This is an author version based on a template by Elsevier.
 5 
4.3.4.  Ester 11.  To a stirred solution of carboxylic acid 10 (234 
mg, 0.473 mmol) in dry THF (8.6 mL) under a nitrogen 
atmosphere were added triethylamine (72 µL, 0.52 mmol) and 
2,4,6-trichlorobenzoyl chloride (81 µL, 0.52 mmol). After the 
mixture was stirred for 5 h at room temperature, the precipitate 
was removed by centrifugation. After the precipitate was washed 
with dry THF (4 mL), the combined filtrates and washings were 
concentrated in vacuo and dissolved in dry benzene (11.8 mL). 
To the activated ester solution was added a solution of primary 
alcohol 8 (75.3 mg, 0.522 mmol, syn/anti = 93/7) and N,N-
dimethyl-4-aminopyridine (124 mg, 1.02 mmol) in dry benzene 
(4 mL) under a nitrogen atmosphere. After being stirred for 2 h at 
room temperature, the reaction mixture was quenched with sat. 
sodium bicarbonate aq. (10 mL), and extracted with EtOAc (3 
mL ´ 5). The combined extracts were washed with brine, dried 
with Na2SO4, and concentrated. The crude oil was purified with a 
SiO2 column (FL60D, 9 g, hexane / EtOAc = 49/1 to 4/1) to give 
ester 11 (269 mg, 92%, syn/anti = 99/1, E/Z = 6.1/1) as a 
colorless oil. 11: Rf 0.60 (hexane / EtOAc = 5:1); [a]D25 +26.8 (c 
1.31, CHCl3); 1H NMR (600 MHz, CDCl3) d 7.68–7.64 (m, 4H), 
7.46–7.37 (m, 6H), 6.38 (dt, J = 14.5, 7.4 Hz, 1H), 5.95 (d, J = 
14.5 Hz, 1H), 5.76 (ddt, J = 17.2, 10.1, 7.1 Hz, 1H), 5.10 (d, J = 
17.2 Hz, 1H), 5.06 (d, J = 10.1 Hz, 1H), 4.20 (tt, J = 5.9, 5.9 Hz, 
1H), 3.99 (dd, J = 10.7, 6.8 Hz, 1H), 3.87 (dd, J = 10.7, 6.8 Hz, 
1H), 3.31 (s, 3H), 3.16 (dt, J = 3.7, 6.5 Hz, 1H), 2.45 (dd, J = 6.5, 
5.9 Hz, 2H), 2.34 (m, 1H), 2.27–2.15 (m, 3H), 1.90 (m, 1H), 1.04 
(s, 9H), 0.87 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, CDCl3) d 
170.9 (s), 141.8 (d), 135.9 (d, 2C), 135.8 (d, 2C), 134.9 (d), 133.6 
(s), 133.5 (s), 129.8 (d, 2C), 127.7 (d, 2C), 127.6 (d, 2C), 117.1 
(t), 80.9 (d), 77.8 (d), 69.0 (d), 66.8 (t), 58.0 (q), 43.1 (t), 41.5 (t), 
35.4 (d), 35.3 (t), 26.9 (q, 3C), 19.2 (s), 11.0 (q); IR (CHCl3) 
3074, 3054, 3010, 2962, 2933, 2897, 2860, 2829, 1729, 1641, 
1472, 1428, 1363, 1233, 1190, 1105, 998, 952, 920, 822, 735, 
704 cm–1; HRMS (ESI) m/z 643.1729 (calcd for C30H41INaO4Si 
[M+Na]+, D +1.3 mmu). 
4.3.5.  Allylic alcohol 13.  To a stirred solution of (–)-aldehyde 
12 (23.3 mg, 70.8 µmol) and ester 11 (65.9 mg, 106 µmol, E/Z = 
6.1/1) in degassed dry THF / DMF (3:1, 1.3 mL) under an argon 
atmosphere was added a 99:1 (w/w) mixture of chromium 
chloride (II) – nickel chloride (II) (56.5 mg, CrCl2 455 µmol and 
NiCl2 4.36 µmol). After being stirred for 14 h, the reaction 
mixture was diluted with EtOAc (4 mL), sat. ammonium chloride 
aq. (4 mL), and water (1 mL), and extracted with EtOAc (4 mL ´ 
3). The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated. The crude oil was purified with a SiO2 
column (3.1 g, hexane / CHCl3 / EtOAc = 1/1/0, 3/7/0, 0/1/0, 
0/4/1 and 0/3/1) to give allylic alcohol 13 (42.7 mg, 73%, 5E-
isomer only, ca. 3:2 diastereomer mixture at C7) as a colorless oil. 
13: Rf 0.50 (hexane / acetone = 7:3); [a]D25 +5.7 (c 0.93, CHCl3); 
1H NMR (600 MHz, CDCl3) d 8.32 (s, 0.4H), 8.32 (s, 0.6H), 8.31 
(s, 0.6H), 8.30 (s, 0.4H), 7.72–7.61 (m, 5H), 7.44–7.32 (m, 6H), 
6.67 (dd, J = 17.7, 11.2 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 5.77 
(d, J = 11.2 Hz, 1H), 5.74 (m, 1H), 5.55 (m, 1H), 5.39 (m, 1H), 
5.08 (d, J = 17.2 Hz, 1H), 5.03 (d, J = 10.2 Hz, 1H), 4.30–4.26 
(m, 0.4H), 4.26 (d, J = 7.9 Hz, 0.6H), 4.25–4.19 (m, 0.6H), 4.17 
(d, J = 7.8 Hz, 0.4H), 4.01 (m, 1H), 3.97 (m, 1H), 3.84 (m, 1H), 
3.30 (s, 1.2H), 3.30 (s, 1.8H), 3.29 (s, 1.8H), 3.28 (s, 1.2H), 3.16 
(m, 1H), 2.51–2.43 (m, 2H), 2.36–2.12 (m, 6H), 1.89 (m, 1H), 
1.02 (s, 9H), 0.87 (d, J = 6.8 Hz, 1.2H), 0.86 (d, J = 6.8 Hz, 
1.8H), 0.75 (d, J = 7.1 Hz, 1.2H), 0.65 (d, J = 6.9 Hz, 1.8H); 13C 
NMR (150 MHz, CDCl3) d 171.34 [171.27], 161.90 [161.89], 
156.0, 155.3 [155.0], 141.0 [140.6], 138.96 [138.95], 138.43 
[138.39], 136.7 [136.5], 135.8 (4C), 134.9 [134.8], 134.3, 134.0 
[133.9], 133.7 (2C), 131.54 [131.50], 130.7, 129.7 [129.6], 127.8, 
127.5 (4C), 126.4 [124.2], 122.5, 117.0, 80.9, 80.1 [79.9], 75.7 
[73.0], 70.2 [70.1], 66.6, 58.0 [57.5], 57.2 [56.9], 42.5, 42.1, 
41.5 [41.4], 40.0, 39.8, 35.3, 26.9, 19.2, 12.0, 11.4, 11.02 [11.01] 
(sprit signals derived from the C7 diastereomer were shown in 
parenthesis); IR (CHCl3) 3673, 3462, 3167, 3072, 3029, 3009, 
2966, 2933, 2899, 2859, 2828, 1729, 1651, 1542, 1462, 1428, 
1380, 1308, 1238, 1218, 1191, 1111, 980, 942, 918, 822 cm–1; 
HRMS (ESI) m/z 846.3741 (calcd for C46H57N3NaO9Si [M+Na]+, 
D –2.1 mmu).  
4.3.6.  RCM precursor 14.  To a stirred solution of allylic alcohol 
13 (26.1 mg, 28.3 µmol) in dry CH2Cl2 (0.63 mL) under a 
nitrogen atmosphere were added pyridine (26 µL) and Dess–
Martin periodinane (20.2 mg, 47.6 µmol). After being stirred for 
2.5 h at 0 °C, the reaction mixture was quenched with a 1:1:1 
mixture of sat. sodium thiosulfate aq. – sat. sodium bicarbonate 
aq. – water (5 mL), and extracted with CH2Cl2 (2 mL ´ 4). The 
combined extracts were washed with brine, dried with Na2SO4, 
and concentrated. The crude oil was purified with a SiO2 column 
(FL60D 2 g, hexane / CHCl3 = 1/1 to 0/1) to give ketone 14 (24.6 
mg, 94%) as a colorless oil. 14: Rf 0.42 (CHCl3 / EtOAc = 4:1); 
[a]D25 –5.5 (c 0.54, CHCl3); 1H NMR (600 MHz, CDCl3) d 8.332 
(s, 1H), 8.327 (s, 1H), 7.70 (s, 1H), 7.70–7.65 (m, 4H), 7.44–7.35 
(m, 6H), 6.83 (dt, J = 15.8, 7.6 Hz, 1H), 6.67 (dd, J = 17.7, 11.3 
Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 6.12 (d, J = 15.8 Hz, 1H), 
5.78 (d, J = 11.3 Hz, 1H), 5.75 (ddt, J = 17.2, 10.2, 7.1 Hz, 1H), 
5.07 (d, J = 17.2 Hz, 1H), 5.04 (d, J = 10.2 Hz, 1H), 4.40 (d, J = 
9.7 Hz, 1H), 4.32 (tt, J = 6.1, 5.9 Hz, 1H), 4.01 (dd, J = 10.8, 6.8 
Hz, 1H), 3.86 (dd, J = 10.8, 6.9 Hz, 1H), 3.44 (dq, J = 9.7, 7.1 Hz, 
1H), 3.31 (s, 3H), 3.21–3.13 (m, 1H), 3.17 (s, 3H), 2.51 (dd, J = 
15.1, 6.1 Hz, 1H), 2.46 (dd, J = 15.1, 6.1 Hz, 1H), 2.47–2.35 (m, 
2H), 2.32 (m, 1H), 2.19 (m, 1H), 1.90 (m, 1H), 1.04 (s, 9H), 0.87 
(d, J = 6.9 Hz, 3H), 0.84 (d, J = 7.1 Hz, 3H); 13C NMR (150 
MHz, CDCl3) d 201.7 (s), 170.9 (s), 161.9 (s), 156.0 (s), 155.5 (s), 
142.8 (d), 140.0 (s), 139.0 (d), 138.5 (d), 137.2 (d), 135.9 (d, 2C), 
135.8 (d, 2C), 134.8 (d), 133.5 (s), 133.4 (s), 132.9 (d), 131.6 (s), 
130.7 (s), 129.9 (d), 129.8 (d), 127.7 (d, 4C), 124.2 (t), 122.6 (d), 
117.1 (t), 80.9 (d), 77.6 (d), 69.2 (d), 66.8 (t), 58.0 (q), 57.0 (q), 
47.0 (d), 41.6 (t), 40.0 (t), 35.3 (d), 35.3 (t), 26.9 (q, 3C), 19.2 (s), 
14.1 (q), 11.0 (q); IR (CHCl3) 3163, 3027, 3010, 2933, 2859, 
1729, 1694, 1665, 1637, 1542, 1462, 1428, 1376, 1308, 1111, 
978, 943, 919, 823, 703 cm–1; HRMS (ESI) m/z 844.3618 (calcd 
for C46H55N3NaO9Si [M+Na]+, D +1.3 mmu). 
4.3.7.  Secondary alcohol 15.  To a stirred solution of ketone 14 
(22.7 mg, 27.6 µmol) in THF (10.2 mL) under a nitrogen 
atmosphere at 0 °C were added a 1 M solution of tetra-n-
butylammonium fluoride in THF (0.86 mL, 0.86 mmol) and 
acetic acid (49 µL). After being stirred for 18 h at room 
temperature, the reaction mixture was diluted with sat. sodium 
bicarbonate aq. (10 mL) and extracted with EtOAc (5 mL ´ 4). 
The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated. The crude oil was purified with SiO2 
columns (FL60D 1.2 g, CHCl3 / EtOAc = 4/1 to 1/1; FL60D 0.4 
g, EtOAc) to give secondary alcohol 15 (11.6 mg, 72%) as a 
colorless oil. 15: Rf 0.66 (CHCl3 / MeOH = 10:1); [a]D25 –39.7 (c 
0.46, CHCl3); 1H NMR (600 MHz, CDCl3) d 8.34 (s, 1H), 8.33 (s, 
1H), 7.71 (s, 1H), 6.97 (dt, J = 15.8, 7.3 Hz, 1H), 6.67 (dd, J = 
17.7, 11.5 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 6.29 (d, J = 15.8 
Hz, 1H), 5.78 (d, J = 11.5 Hz, 1H), 5.77 (ddt, J = 17.8, 10.0, 7.3 
Hz, 1H), 5.11 (d, J = 17.8 Hz, 1H), 5.06 (d, J = 10.0 Hz, 1H), 
4.42 (d, J = 9.6 Hz, 1H), 4.21 (m, 1H), 4.12 (dd, J = 10.9, 7.0 Hz, 
1H), 4.05 (dd, J = 10.9, 6.5 Hz, 1H), 3.56 (dq, J = 9.6, 7.1 Hz, 
1H), 3.35 (s, 3H), 3.34 (m, 1H), 3.23 (dt, J = 3.5, 6.5 Hz, 1H), 
3.19 (s, 3H), 2.55 (dd, J = 16.6, 3.1 Hz, 1H), 2.48 (dd, J = 16.6, 
9.2 Hz, 1H), 2.52–2.40 (m, 2H), 2.36 (m, 1H), 2.21 (m, 1H), 2.04 
(m, 1H), 0.93 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 7.1 Hz, 3H); 13C 
NMR (150 MHz, CDCl3) d 202.0 (s), 172.4 (s), 161.9 (s), 156.0 
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(s), 155.6 (s), 142.8 (d), 139.8 (s), 139.0 (d), 138.6 (d), 137.2 
(d), 134.8 (d), 132.9 (d), 131.6 (s), 130.7 (s), 124.2 (t), 122.6 (d), 
117.6 (t), 81.3 (d), 77.7 (d), 67.1 (d), 66.8 (t), 58.0 (q), 57.0 (q), 
46.8 (d), 41.0 (t), 39.4 (t), 35.2 (d), 35.1 (t), 14.2 (q), 11.1 (q); IR 
(CHCl3) 3674, 3481, 3168, 3079, 3010, 2934, 2826, 1720, 1665, 
1628, 1542, 1459, 1377, 1233, 1222, 1210, 1187, 1092, 980, 943, 
919, 787, 771, 756, 741, 731 cm–1; HRMS (ESI) m/z 606.2411 
(calcd for C30H37N3NaO9 [M+Na]+, D –1.6 mmu). 
4.3.8.  Macrolactone 16.  To a stirred solution of ketone 14 (7.8 
mg, 9.5 µmol) in dry CH2Cl2 (8.8 mL) under a nitrogen 
atmosphere was added a 2 mM solution of 2nd generation 
Hoveyda–Grubbs catalyst in dry CH2Cl2 (1.4 mL, 2.8 µmol). 
After being stirred for 9 h at reflux, the reaction mixture was 
concentrated. The crude material was purified with a SiO2 
column (FL60D 0.5 g, hexane / EtOAc = 2/1 to 1/1) to give 
macrolactone (E)-16 (4.0 mg, 53%), its stereoisomer (Z)-16 (2.2 
mg, 29%), and its dimer (0.8 mg, 5%) as colorless oils. (E)-16: Rf 
0.16 (CHCl3 / EtOAc = 4:1); [a]D25 –38.1 (c 0.63, CHCl3); 1H 
NMR (600 MHz, CDCl3) d 8.13 (s, 1H), 8.08 (s, 1H), 7.71–7.66 
(m, 4H), 7.66 (s, 1H), 7.44–7.35 (m, 6H), 7.07 (td, J = 7.6, 15.8 
Hz, 1H), 6.94 (td, J = 7.2, 16.2 Hz, 1H), 6.35 (d, J = 15.8 Hz, 
1H), 5.97 (d, J = 16.2 Hz, 1H), 4.45 (m, 1H), 4.36 (d, J = 9.6 Hz, 
1H), 4.13 (qd, J = 7.0, 9.6 Hz, 1H), 4.00 (dd, J = 6.8, 10.4 Hz, 
1H), 3.92 (dd, J = 6.8, 10.4 Hz, 1H), 3.39 (m, 1H), 3.35 (s, 3H), 
3.09 (s, 3H), 2.77 (m, 1H), 2.72 (dd, J = 5.6, 15.6 Hz, 1H), 2.66 
(dd, J = 6.8, 15.6 Hz, 1H), 2.45 (m, 2H), 2.42 (m, 1H), 2.06 (ddtq, 
J = 2.0, 6.8, 6.8, 6.8 Hz, 1H), 1.02 (s, 9H), 0.88 (d, J = 6.8 Hz, 
3H), 0.81 (d, J = 7.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) d 
203.2 (s), 171.1 (s), 162.7 (s), 156.5 (s), 155.6 (s), 143.3 (d), 
139.6 (d), 139.0 (s), 137.4 (d), 137.3 (d), 137.2 (d), 135.9 (d, 2C), 
135.83 (d, 2C), 135.0 (d), 133.7 (s), 133.6 (s), 131.5 (s), 130.3 (s), 
129.9 (d), 129.7 (d), 127.7 (d, 2C), 127.6 (d, 2C), 116.3 (d), 79.7 
(d), 76.7 (d), 68.7 (d), 67.5 (t), 57.7 (q), 56.2 (q), 42.6 (d), 41.7 
(t), 40.3 (t), 35.0 (d), 32.4 (t), 26.9 (t, 3C), 19.2 (s), 14.9 (q), 9.3 
(q); IR (CHCl3) 3160, 3005, 2932, 2856, 1731, 1662, 1560, 1485, 
1424, 1220, 1209, 1181, 1104, 997, 979, 909, 821, 790, 721, 703 
cm–1; HRMS (ESI) m/z 816.3320 (calcd for C44H51N3O9SiNa 
[M+Na]+, D +2.8 mmu). (Z)-16: Rf 0.21 (CHCl3 / EtOAc = 4:1); 
[a]D25 –67.8 (c 0.57, CHCl3); 1H NMR (600 MHz, CDCl3) d 8.13 
(s, 1H), 8.10 (s, 1H), 7.69–7.62 (m, 4H), 7.61 (s, 1H), 7.44–7.35 
(m, 6H), 6.84 (td, J = 6.8, 16.0 Hz, 1H), 6.43 (td, J = 7.6, 11.8 Hz, 
1H), 6.33 (d, J = 11.8 Hz, 1H), 6.01 (d, J = 16.0 Hz, 1H), 4.38–
4.29 (m, 1H), 4.35 (d, J = 8.4 Hz, 1H), 4.16 (dd, J = 5.2, 10.8 Hz, 
1H), 3.95 (m, 1H), 3.94 (dd, J = 7.6, 10.8 Hz, 1H), 3.50–3.41 (m, 
2H), 3.37 (s, 3H), 3.16 (s, 3H), 2.88 (m, 1H), 2.60 (dd, J = 6.4, 
15.8 Hz, 1H), 2.53 (dd, J = 6.4, 15.8 Hz, 1H), 2.40 (m, 2H), 2.19 
(m, 1H), 1.07 (d, J = 6.8 Hz, 3H), 1.02 (s, 9H), 0.93 (d, J = 6.8 
Hz, 3H); 13C NMR (150 MHz, CDCl3) d 202.5 (s), 170.9 (s), 
161.7 (s), 156.6 (s), 155.7 (s), 142.7 (d), 141.1 (d), 139.3 (s), 
137.6 (d), 137.4 (d), 137.0 (d), 135.80 (d, 2C), 135.79 (d, 2C), 
134.7 (d), 133.7 (s), 133.5 (s), 131.6 (s), 130.7 (s), 129.83 (d), 
129.78 (d), 127.71 (d, 2C), 127.67 (d, 2C), 114.3 (d), 81.7 (d), 
77.6 (d), 69.0 (d), 66.9 (t), 58.3 (q), 56.9 (q), 44.0 (d), 41.0 (t), 
39.4 (t), 36.8 (d), 31.9 (t), 26.9 (q, 3C), 19.2 (s), 14.0 (q), 12.6 
(q); IR (CHCl3) 3162, 3005, 2932, 2856, 1730, 1663, 1558, 1458, 
1424, 1179, 1103, 980, 917, 820, 790, 758, 739, 702 cm–1; 
HRMS (ESI) m/z 816.3318 (calcd for C44H51N3O9SiNa [M+Na]+, 
D +2.4 mmu).  
4.3.9.  Mycalolide macrolactone analog (E)-3.  To a stirred 
solution of silyl ether (E)-16 (7.7 mg, 9.7 µmol) in THF (3.7 mL) 
under a nitrogen atmosphere at 0 °C were added a 1 M solution 
of tetra-n-butylammonium fluoride in THF (0.29 mL, 0.29 
mmol) and acetic acid (16.5 µL, 0.29 mmol). After being stirred 
for 60 h at room temperature, the reaction mixture was diluted 
with sat. sodium bicarbonate aq. (5 mL), and extracted with 
EtOAc (5 mL × 3). The combined extracts were washed with 
brine, dried with Na2SO4, and concentrated. The crude oil was 
purified with a SiO2 column (FL60D 0.5 g, hexane / EtOAc = 3/7 
to 1/9) to give (E)-lactone 3 (4.7 mg, 87%) as a colorless oil. (E)-
3: Rf 0.30 (hexane/EtOAc = 1/9); [a]D25 –54 (c 0.38, CHCl3); 1H 
NMR (600 MHz, CDCl3) d 8.12 (s, 1H), 8.08 (s, 1H), 7.66 (s, 
1H), 7.05 (dt, J = 15.8, 7.7 Hz, 1H), 7.04 (dt, J = 15.9, 7.5 Hz, 
1H), 6.35 (dt, J = 15.8, 1.6 Hz, 1H), 6.23 (dt, J = 15.9, 1.3 Hz, 
1H), 4.40 (d, J = 8.9 Hz, 1H), 4.34 (m, 1H), 4.16 (dd, J = 10.7, 
8.2 Hz, 1H), 4.10 (m, 1H), 4.04 (dd, J = 10.7, 5.9 Hz, 1H), 4.00 
(dt, J = 8.9, 7.0 Hz, 1H), 3.53 (ddd, J = 10.2, 4.7, 2.6 Hz, 1H), 
3.39 (s, 3H), 3.15 (s, 3H), 2.78 (dddd, J = 14.8, 7.7, 4.7, 1.6 Hz, 
1H), 2.71 (dd, J = 15.8, 2.9 Hz, 1H), 2.61 (dd, J = 15.8, 10.0 Hz, 
1H), 2.57–2.54 (m, 2H), 2.41 (dddd, J = 14.8, 10.2, 7.7, 1.6 Hz, 
1H), 2.05 (m, 1H), 0.93 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 7.0 Hz, 
3H); 13C NMR (150 MHz, CDCl3) d 202.6, 172.3, 162.7, 156.5, 
155.5, 143.6, 139.8, 139.2, 137.4, 137.3, 137.2, 134.2, 131.3, 
130.1, 116.3, 79.2, 77.1, 67.2, 66.9, 57.9, 56.6, 43.6, 41.5, 40.4, 
35.7, 33.2, 13.8, 9.5; IR (CHCl3) 3690, 3167, 3026, 3003, 2929, 
2846, 1719, 1661, 1609, 1563, 1458, 1386, 1261, 1215, 1091, 
1100, 1023, 977, 918 cm–1; HRMS (ESI) m/z 578.2087 (calcd for 
C28H33N3NaO9 [M+Na]+, D –2.7 mmu).    
4.3.10.  Mycalolide macrolactone analog (Z)-3.  To a stirred 
solution of silyl ether (Z)-16 (3.3 mg, 4.2 µmol) in THF (1.6 mL) 
under a nitrogen atmosphere at 0 °C were added a 1 M solution 
of tetra-n-butylammonium fluoride in THF (0.125 mL, 125 
µmol) and acetic acid (7.1 µL, 125 µmol). After being stirred for 
48 h at room temperature, the reaction mixture was diluted with 
sat. sodium bicarbonate aq. (5 mL), and extracted with EtOAc (5 
mL ´ 4). The combined extracts were washed with brine, dried 
with Na2SO4, and concentrated. The crude oil was purified with a 
SiO2 column (FL60D 0.5 g, hexane / EtOAc = 1/9) to give (Z)-
lactone 3 (2.1 mg, 91%) as a colorless oil. (Z)-3: Rf 0.39 
(hexane/EtOAc = 1/9); [a]D25 –71 (c 0.36, CHCl3); 1H NMR (600 
MHz, CDCl3) d 8.17 (s, 1H), 8.14 (s, 1H), 7.63 (s, 1H), 6.91 (dt, 
J = 16.1, 6.7 Hz, 1H), 6.42 (dt, J = 11.7, 7.5 Hz, 1H), 6.35 (d, J = 
11.7 Hz, 1H), 6.18 (d, J = 16.1 Hz, 1H), 4.37 (d, J = 7.5 Hz, 1H), 
4.18 (m, 1H), 4.16 (dd, J = 10.9, 5.3 Hz, 1H), 4.09 (dd, J = 10.9, 
5.6 Hz, 1H), 3.89 (qd, J = 7.1, 7.5 Hz, 1H), 3.75 (br s, 1H), 3.51 
(dt, J = 4.7, 6.6 Hz, 1H), 3.40 (s, 3H), 3.36 (dddd, J = 16.2, 7.5, 
4.7, 1.4 Hz, 1H), 3.24 (s, 3H), 3.08 (dddd, J = 16.2, 7.5, 6.6, 1.4 
Hz, 1H), 2.60 (dd, J = 16.0, 3.2 Hz, 1H), 2.51 (dd, J = 16.0, 9.5 
Hz, 1H), 2.46–2.41 (m, 2H), 2.15 (m, 1H), 1.08 (d, J = 7.0 Hz, 
3H), 1.01 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) d 
202.2, 172.2, 161.8, 156.6, 155.6, 143.4, 140.4, 139.7, 137.9, 
137.7, 136.8, 133.9, 131.4, 130.6, 114.6, 81.0, 78.2, 67.0, 66.8, 
58.1, 57.3, 44.3, 41.2, 39.6, 37.0, 31.4, 13.5, 12.7; IR (CHCl3) 
3675, 3167, 3026, 3007, 2931, 2846, 1724, 1663, 1557, 1459, 
1377, 1279, 1261, 1220, 1182, 1100, 1013, 975, 918 cm–1; 
HRMS (ESI) m/z 578.2091 (calcd for C28H33N3NaO9 [M+Na]+, D 
–2.3 mmu). 
4.3.11.  Ring-closing metathesis of 15.  To a stirred solution of 
secondary alcohol 15 (5.8 mg, 9.9 µmol) in dry CH2Cl2 (9.2 mL) 
under a nitrogen atmosphere was added a 2 mM solution of 2nd 
generation Hoveyda–Grubbs catalyst in dry CH2Cl2 (1.5 mL, 3.0 
µmol). After being stirred for 37 h at reflux, the reaction mixture 
was concentrated. The crude material was purified with SiO2 
columns (FL60D 0.5 g, CHCl3 / MeOH = 100/1 to 10/1; FL60D 
0.5 g, hexane / EtOAc = 3/7 to 1/9) to give macrolactone (E)-3 
(2.9 mg, 52%), its stereoisomer (Z)-3 (1.1 mg, 20%), and its 
dimer (0.8 mg, 7%) as colorless oils. 
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4.4 Bioassay of mycalolide B and its synthetic analogs 
The cytotoxicities of the probes and model compounds were 
measured by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) method.19a The actin-
depolymerizing activities of the compounds were measured 
based on their ability to attenuate the fluorescence of pyrene-
conjugated (pyrenyl) actin, as previously described.12a 
Antimycotic assays against several fungi were conducted at 
Ricerca Biosciences Inc. (Taipei, Taiwan). 
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